Immunoblastic Lymphadenopathy: all 135 studies

Page 1 of 2. Open to participants first (13), then studies with results posted, then the rest; newest registration first within each.

• Azacitidine and Abatacept in Relapsed or Refractory T-Cell LymphomaRecruitingNCT07388563Phase 1
• Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell LymphomaRecruitingNCT07300514Phase 3
• Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell LymphomaRecruitingNCT06561048Phase 3
• A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) PhenotypeRecruitingNCT06522737Phase 3
• A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.RecruitingNCT06393738Phase 1
• Clinical Study of Mitoxantrone Liposome and Azacitidine in the Treatment of R/R AITLRecruitingNCT06224842Phase 1/2
• A Registry for People With T-cell LymphomaRecruitingNCT05978141
• A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
• Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell LymphomaRecruitingNCT04803201Phase 2
• Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin LymphomaRecruitingNCT04234048Phase 1
• A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or LymphomaRecruitingNCT03017820Phase 1
• Registry of Older Patients With CancerRecruitingNCT01137825
• Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic CancerRecruitingNCT01137643
• Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell LymphomasActive, not recruitingNCT03598998Phase 1/2Results posted
• Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell LymphomaTerminatedNCT03590574Phase 1/2Results posted
• Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell NeoplasmsCompletedNCT03493451Phase 2Results posted
• Study of Pembrolizumab (MK-3475) in Combination With RomidepsinActive, not recruitingNCT03278782Phase 1/2Results posted
• Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell LymphomaActive, not recruitingNCT03113500Phase 2Results posted
• Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell LymphomaTerminatedNCT03075553Phase 2Results posted
• A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaTerminatedNCT03070964Phase 2Results posted
• A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)CompletedNCT02588651Phase 2Results posted
• Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's LymphomaCompletedNCT02561273Phase 1/2Results posted
• Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 MutationCompletedNCT02273739Phase 1/2Results posted
• Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell LymphomaCompletedNCT02232516Phase 2Results posted
• Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01839916Phase 2Results posted
• Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ LymphomasTerminatedNCT01805037Phase 1/2Results posted
• Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedNCT01769222Phase 1Results posted
• Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid MalignanciesTerminatedNCT01678443Phase 1Results posted
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic MalignanciesCompletedNCT01529827Phase 2Results posted
• Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin LymphomaCompletedNCT01466881Phase 2Results posted
• Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological MalignanciesCompletedNCT01427881Phase 2Results posted
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell TransplantTerminatedNCT01419795Phase 2Results posted
• Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin LymphomaTerminatedNCT01408043Not applicableResults posted
• Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin LymphomaCompletedNCT01336933Phase 2Results posted
• Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid TumorsCompletedNCT01326702Phase 1/2Results posted
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic MalignanciesCompletedNCT01273766Phase 2Results posted
• Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin LymphomaCompletedNCT01261247Phase 2Results posted
• Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaCompletedNCT01258998Phase 2Results posted
• Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple MyelomaCompletedNCT01110135Phase 2Results posted
• Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin LymphomaCompletedNCT01075321Phase 1/2Results posted
• Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin LymphomaCompletedNCT00918333Phase 1/2Results posted
• Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure DisordersCompletedNCT00856388Not applicableResults posted
• Study of MLN8237 in Participants With Advanced Hematological MalignanciesCompletedNCT00697346Phase 1Results posted
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin LymphomaCompletedNCT00644189Phase 1/2Results posted
• Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell LymphomaCompletedNCT00601718Phase 1/2Results posted
• Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other DisordersActive, not recruitingNCT00544115Phase 2Results posted
• Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's LymphomaCompletedNCT00131937Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerCompletedNCT00118352Phase 2Results posted
• Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple MyelomaTerminatedNCT00112723Phase 1/2Results posted
• Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without CancerCompletedNCT00112593Not applicableResults posted
• Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic CancerCompletedNCT00089011Phase 2Results posted
• Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid MalignanciesCompletedNCT00072514Phase 2Results posted
• Cyclosporine in Treating Patients With Recurrent or Refractory Angioimmunoblastic T-Cell LymphomaTerminatedNCT00070291Phase 2Results posted
• Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancerCompletedNCT00049504Phase 2Results posted
• Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological MalignanciesCompletedNCT00040846Phase 2Results posted
• A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)SuspendedNCT07055477Phase 1
• Clinical Study of CEP+Dasatinib + Azacytidine in First-line Treatment of. Angioimmunoblastoma ForesightActive, not recruitingNCT07046182Phase 4
• A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell LymphomaSuspendedNCT06761677Phase 1/2
• Tazemetostat Plus CHOP in 1L T-cell LymphomaWithdrawnNCT06692452Phase 2
• A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)Active, not recruitingNCT06035497Phase 1/2
• Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.Status unknownNCT05821192Not applicable
• Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic MalignanciesSuspendedNCT05377827Phase 1
• Anti-CD7 CAR-T Cell Therapy for Relapse and Refractory CD7 Positive T Cell MalignanciesCompletedNCT05290155Phase 1
• An Exploratory Clinical Study Evaluating the Safety and Efficacy of Anti CD30 CAR T Cells in Patients With CD30+ Relapsed/Refractory LymphomaStatus unknownNCT05208853Early Phase 1
• Azacytidine Plus Chidamide in the Treatment of Relapsed and Refractory Angioimmunoblastic T-cell LymphomaStatus unknownNCT05179213Phase 2
• Sintilimab in Combination With Chidamide in Refractory and Relapsed AITLStatus unknownNCT04831710Phase 2
• Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell MalignanciesSuspendedNCT04828174Phase 1
• Brentuximab Vedotin and Pembrolizumab in Treating Patients With Recurrent Peripheral T-Cell LymphomaWithdrawnNCT04795869Phase 2
• CD7-CART in the Treatment of r / r CD7 Positive Hemolymph System Malignancies on Increasing Dose and Open Label StudyStatus unknownNCT04480788Phase 1
• Rituximab Combined With Chidamide and Lenalidomide for r/r AITLStatus unknownNCT04319601Not applicable
• Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte MalignanciesStatus unknownNCT04008394Phase 1
• Study Evaluating the Safety and Efficacy of C-CHOP in Untreated Subjects With Angioimmunoblastic T Cell LymphomaStatus unknownNCT03853044Phase 2
• Efficacy and Safety of Oral Azacitidine Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory AITLCompletedNCT03593018Phase 3
• Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)Status unknownNCT03273452Phase 2
• Risk Stratification of Nodal PTCLCompletedNCT03040206
• CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and LymphomaStatus unknownNCT02742727Phase 1/2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin LymphomaCompletedNCT02652715Not applicable
• CEOP/IVE/GDP Compared With CEOP as the First-line Therapy for Newly Diagnosed Adult Patients With PTCLStatus unknownNCT02533700Phase 2
• Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell LymphomasCompletedNCT02223208Phase 1/2
• CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin LymphomaCompletedNCT02168140Phase 1
• Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell TransplantCompletedNCT01959477Early Phase 1
• Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D InsufficiencyActive, not recruitingNCT01787409Not applicable
• Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin LymphomaWithdrawnNCT01769911Not applicable
• MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or LymphomaCompletedNCT01748721Phase 1
• CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell LymphomaStatus unknownNCT01746992Phase 4
• CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II StudyStatus unknownNCT01719835Phase 2
• Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
• Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT01590732Phase 1
• Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell LymphomaCompletedNCT01567709Phase 1
• Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)CompletedNCT01553786Phase 2
• Carfilzomib in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01336920Phase 1
• Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic CancersCompletedNCT01254578Phase 1
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell TransplantActive, not recruitingNCT01199562
• RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell LymphomasCompletedNCT01198665Phase 1/2
• High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin LymphomaCompletedNCT01177371Phase 2
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid TumorsCompletedNCT01158274Phase 1
• AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or LymphomaCompletedNCT01129193Phase 1
• Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell LymphomaCompletedNCT01129180Phase 1
• Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin LymphomaTerminatedNCT01116154Phase 1

← Immunoblastic Lymphadenopathy overview